NEW YORK, Feb. 6, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aratana Therapeutics, Inc. ("Aratana" or the "Company") (NASDAQ: PETX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
The investigation concerns whether Aratana and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here to join a class action]
On February 6, 2017, Aratana disclosed that the Center for Veterinary Medicine ("CVM") had requested more information about the Company's appetite stimulation drug ENTYCE. Aratana advised investors that it "now anticipates that ENTYCE . . . will be commercially available by late 2017" and that the CVM's request was "in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale."
On this news, Aratana stock has fallen as much as $1.53, or 19.05%, to a low of $6.50 during intraday trading on February 6, 2017.
The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-aratana-therapeutics-inc--petx-300402517.html
SOURCE Pomerantz LLP
